We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in personalized treatment of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations.

Latest news

September 23, 2016

Switzerland's AC Immune Opens For Trading On NASDAQ

September 23, 2016

AC Immune SA Announces Pricing of Upsized Initial Public Offering

September 13, 2016

AC Immune SA Commences Proposed Initial Public Offering of Common Shares

Company information

Discover more about us, who we are, and how we innovate to improve neurodegenerative disease understanding and develop breakthrough therapies.

Product pipeline

One of the world’s largest Alzheimer’s product pipelines with complementary diagnostic agents driven by proprietary technology platforms.

Stock information

Up to date company stock information and analytics directly from Nasdaq